|
SLC6A6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.43870487640174E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.31669997127659E-09 |
| Normal-vs-Stage2 |
2.873400E-01 |
| Normal-vs-Stage3 |
3.10769999956051E-07 |
| Normal-vs-Stage4 |
2.38879999999719E-05 |
| Stage1-vs-Stage2 |
2.421700E-02 |
| Stage1-vs-Stage3 |
4.614800E-01 |
| Stage1-vs-Stage4 |
9.283200E-01 |
| Stage2-vs-Stage3 |
1.323870E-02 |
| Stage2-vs-Stage4 |
3.524400E-02 |
| Stage3-vs-Stage4 |
6.039600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.60271795834888E-12 |
| Normal-vs-AfricanAmerican |
2.372400E-02 |
| Normal-vs-Asian |
1.099240E-03 |
| Caucasian-vs-AfricanAmerican |
6.585000E-01 |
| Caucasian-vs-Asian |
7.289800E-01 |
| AfricanAmerican-vs-Asian |
5.905200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.88599999997974E-06 |
| Normal-vs-Female |
1.54670054541839E-10 |
| Male-vs-Female |
6.228200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.43760000149396E-08 |
| Normal-vs-Age(41-60Yrs) |
2.13980000385305E-09 |
| Normal-vs-Age(61-80Yrs) |
7.223900E-03 |
| Normal-vs-Age(81-100Yrs) |
4.584000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.562400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.450300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.976000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.864500E-03 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.684000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.933800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.784800E-01 |
| Classical-VS-Follicular |
<1E-12 |
| Classical-VS-Other |
9.097000E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
2.12530000043287E-07 |
| Tall-VS-Other |
9.127600E-01 |
| Tall-VS-Normal |
3.35250000005338E-06 |
| Follicular-VS-Other |
1.698570E-01 |
| Follicular-VS-Normal |
5.259500E-02 |
| Other-VS-Normal |
2.741800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.013700E-04 |
| Normal-vs-N1 |
1.67644999999883E-05 |
| N0-vs-N1 |
2.088100E-02 |
|
|
